Sangamo Therapeutics (SGMOQ) Cash from Operations (2010 - 2025)

Sangamo Therapeutics' Cash from Operations history runs 16 years deep, the most recent figure standing at 24403000.0 for Q4 2025.

• On a quarterly basis, Cash from Operations fell 628.23% year-over-year to 24403000.0 in Q4 2025; TTM through Dec 2025 was 97208000.0, a 44.79% decrease from a year earlier, with the FY2025 full-year figure at 97208000.0, down 44.79% from the prior year.
• Cash from Operations improved to 24403000.0 in Q4 2025 per SGMOQ's latest filing, from 28498000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 11759000.0 in Q3 2024 and bottomed at 68550000.0 in Q1 2021.
• The 5-year median for Cash from Operations is 51552500.0 (2021), against an average of 42303350.0.
• Across the five-year window, Cash from Operations slumped 1127.33% in 2021 and soared 124.86% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 52714000.0 in 2021, then decreased by 8.22% to 57049000.0 in 2022, then gained by 11.41% to 50538000.0 in 2023, then jumped by 93.37% to 3351000.0 in 2024, then plunged by 628.23% to 24403000.0 in 2025.
• Per Business Quant, the three latest SGMOQ Cash from Operations figures stand at 24403000.0 (Q4 2025), 28498000.0 (Q3 2025), and 18158000.0 (Q2 2025).